Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Linear regression analysis. by Young Kyu Lee (14076058)

“…</p><p> Conclusion </p><p>The HTRT group showed a greater decrease in HU both pre- and post-treatment, indicating a possible indirect marker of tumor necrosis. …”

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Table_2_Maternal oral probiotic use is associated with decreased breastmilk inflammatory markers, infant fecal microbiome variation, and altered recognition memory responses in infants—a pilot observational study.XLSX by Sara Gonia (14132166)

“…Probiotic use has been proposed as a strategy to promote health via modulation of microbiomes. …”

Table_1_Maternal oral probiotic use is associated with decreased breastmilk inflammatory markers, infant fecal microbiome variation, and altered recognition memory responses in infants—a pilot observational study.XLSX by Sara Gonia (14132166)

“…Probiotic use has been proposed as a strategy to promote health via modulation of microbiomes. …”

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

PDRN decreases the expression of cellular aging markers. by Jingjing Chen (293564)

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Processing of wakefulness and sleep EEG data to calculate the HFD in a representative subject. by Francesco Colussi (22421582)

KAP assessment scores (n = 422). by Chikondi Maluwa (20660522)

Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

Changes in HSA outcomes between baseline and six months (N = 60). by Janelli Vallin (14540858)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast. by Jad Doughman (20636304)

“…<p>Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast.…”

Socio-demographic characteristics of hypertensive patients’ caregivers (n = 422). by Chikondi Maluwa (20660522)